Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Sho Miyamoto, Takeshi Arashiro, Yu Adachi, Saya Moriyama, Hitomi Kinoshita, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Ryutaro Kotaki, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Keita Ishijima, Eun-Sil Park, Yusuke Inoue, Yoshihiro Kaku, Minoru Tobiume, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Kenzo Tokunaga, Seiya Ozono, Takuya Hemmi, Akira Ueno, Noriko Kishida, Shinji Watanabe, Kiyoko Nojima, Yohei Seki, Takuo Mizukami, Hideki Hasegawa, Hideki Ebihara, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, View ORCID ProfileTadaki Suzuki
doi: https://doi.org/10.1101/2021.12.28.21268481
Sho Miyamoto
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Takeshi Arashiro
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
2Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan
Yu Adachi
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Saya Moriyama
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Hitomi Kinoshita
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Takayuki Kanno
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Shinji Saito
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Harutaka Katano
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Shun Iida
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Akira Ainai
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Ryutaro Kotaki
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Souichi Yamada
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Yudai Kuroda
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Tsukasa Yamamoto
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Keita Ishijima
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Eun-Sil Park
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Yusuke Inoue
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Yoshihiro Kaku
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Minoru Tobiume
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Naoko Iwata-Yoshikawa
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Nozomi Shiwa-Sudo
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Kenzo Tokunaga
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Seiya Ozono
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Takuya Hemmi
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Akira Ueno
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Noriko Kishida
6Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases; Tokyo 208-0011, Japan
Shinji Watanabe
6Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases; Tokyo 208-0011, Japan
Kiyoko Nojima
7Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases; 208-0011, Japan
Yohei Seki
7Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases; 208-0011, Japan
Takuo Mizukami
7Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases; 208-0011, Japan
Hideki Hasegawa
6Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases; Tokyo 208-0011, Japan
Hideki Ebihara
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Ken Maeda
5Department of Veterinary Science, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Shuetsu Fukushi
4Department of Virology I, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Yoshimasa Takahashi
3Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases; Tokyo 162-8640, Japan
Tadaki Suzuki
1Department of Pathology, National Institute of Infectious Diseases; Tokyo, 162-8640, Japan
Article usage
Posted January 01, 2022.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Sho Miyamoto, Takeshi Arashiro, Yu Adachi, Saya Moriyama, Hitomi Kinoshita, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Ryutaro Kotaki, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Keita Ishijima, Eun-Sil Park, Yusuke Inoue, Yoshihiro Kaku, Minoru Tobiume, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Kenzo Tokunaga, Seiya Ozono, Takuya Hemmi, Akira Ueno, Noriko Kishida, Shinji Watanabe, Kiyoko Nojima, Yohei Seki, Takuo Mizukami, Hideki Hasegawa, Hideki Ebihara, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Tadaki Suzuki
medRxiv 2021.12.28.21268481; doi: https://doi.org/10.1101/2021.12.28.21268481
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Sho Miyamoto, Takeshi Arashiro, Yu Adachi, Saya Moriyama, Hitomi Kinoshita, Takayuki Kanno, Shinji Saito, Harutaka Katano, Shun Iida, Akira Ainai, Ryutaro Kotaki, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Keita Ishijima, Eun-Sil Park, Yusuke Inoue, Yoshihiro Kaku, Minoru Tobiume, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Kenzo Tokunaga, Seiya Ozono, Takuya Hemmi, Akira Ueno, Noriko Kishida, Shinji Watanabe, Kiyoko Nojima, Yohei Seki, Takuo Mizukami, Hideki Hasegawa, Hideki Ebihara, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Tadaki Suzuki
medRxiv 2021.12.28.21268481; doi: https://doi.org/10.1101/2021.12.28.21268481
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)